1. Search Result
Search Result
Results for "

24868-20-0

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12542A
    Dantrolene sodium hemiheptahydrate
    Maximum Cited Publications
    7 Publications Verification

    Dantrolene sodium hydrate

    Calcium Channel Autophagy Others
    Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome .
    Dantrolene sodium hemiheptahydrate
  • HY-14657
    Dantrolene sodium
    Maximum Cited Publications
    7 Publications Verification

    F 440

    Calcium Channel Metabolic Disease
    Dantrolene sodium is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ from the sarcoplasm.
    Dantrolene sodium
  • HY-12542
    Dantrolene
    Maximum Cited Publications
    7 Publications Verification

    F 368

    Calcium Channel Autophagy Neurological Disease Inflammation/Immunology
    Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome .
    Dantrolene